Antioxidant activity of BO-653 in orally administered healthy subjects (phase I study)

被引：0
作者：
Mashima, R
Ray, S
O'Halloran, R
Kawabe, Y
Komori, T
Cynshi, O
Stocker, R
机构：
[1] Heart Res Dev PL, Camperdown, NSW 2050, Australia
[2] Heart Res Inst, Camperdown, NSW 2050, Australia
[3] Chugai Pharmaceut Co Ltd, Shizuoka, Japan
来源：
FREE RADICAL BIOLOGY AND MEDICINE | 2002年 / 33卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
371
引用
收藏
页码：S142 / S142
页数：1
相关论文
共 50 条
  • [31] SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A SINGLE ORALLY ADMINISTERED DOSE OF ENPATORAN IN A PHASE I STUDY OF HEALTHY JAPANESE AND CAUCASIAN PARTICIPANTS
    Gopalakrishnan, S.
    Krebs-Brown, A.
    Nogueira Filho, M.
    Kuroki, Y.
    Bachmann, A.
    Becker, A.
    Schippers, F.
    Fluck, M.
    Yalkinoglu, O.
    Klopp-Schulze, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 663 - 664
  • [32] Comment on: “A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-aspartate Angiotensin I in Healthy Subjects”
    Nuggehally R. Srinivas
    [J]. Drugs in R&D, 2017, 17 : 241 - 242
  • [33] Comment on: "A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-aspartate Angiotensin I in Healthy Subjects"
    Srinivas, Nuggehally R.
    [J]. DRUGS IN R&D, 2017, 17 (01) : 241 - 242
  • [34] PHASE-I CLINICAL AND PHARMACOKINETICS STUDY OF ORALLY-ADMINISTERED URIDINE (UR)
    VANGROENINGEN, C
    PETERS, G
    NADAL, J
    LEYVA, A
    GALL, H
    PINEDO, H
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 195 - 195
  • [35] Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
    Conley, BA
    Egorin, MJ
    Tait, N
    Rosen, DM
    Sausville, EA
    Dover, G
    Fram, RJ
    Van Echo, DA
    [J]. CLINICAL CANCER RESEARCH, 1998, 4 (03) : 629 - 634
  • [36] THE EFFECT OF ORALLY ADMINISTERED VERAPAMIL DOSES AND THEIR CORRELATION WITH CARDIOVASCULAR PARAMETERS IN HEALTHY VOLUNTEER SUBJECTS
    Mitic, R.
    Popovic, J.
    Stanojevic, Z.
    Damjanovic, J.
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 110 - 110
  • [37] Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects
    Kok-Onn Lee
    Edmund Feng Tian
    Martin Hui Cai
    Hong Wang
    Yiong-Huak Chan
    Meng-Kwoon Sim
    [J]. Drugs in R&D, 2018, 18 : 51 - 54
  • [38] Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects
    Lee, Kok-Onn
    Tian, Edmund Feng
    Cai, Martin Hui
    Wang, Hong
    Chan, Yiong-Huak
    Sim, Meng-Kwoon
    [J]. DRUGS IN R&D, 2018, 18 (01) : 51 - 54
  • [39] Population Pharmacokinetics (PPK) and Optimal Dosing of Oseltamivir Administered IV and Orally to Healthy Subjects and Subjects with Renal Impairment
    Gibiansky, Leonid
    Giraudon, Mylene
    Rayner, Craig R.
    Brennan, Barbara
    Subramoney, Vishak
    Robson, Richard
    Kamal, Mohamed A.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S14 - S14
  • [40] EXPERIMENTAL DETERMINATION IN HUMAN SUBJECTS OF THE DURATION OF ANTIHISTAMINIC ACTIVITY OF ORALLY ADMINISTERED COMPOUNDS
    PERRY, DJ
    HEARIN, DL
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1949, 13 (01) : 29 - 34
12345